120 related articles for article (PubMed ID: 15470957)
1. Chronotoxicity of nedaplatin in rats.
Cui Y; Sugimoto K; Kawai Y; Sudoh T; Gemba M; Fujimura A
Chronobiol Int; 2004 Jul; 21(4-5):601-11. PubMed ID: 15470957
[TBL] [Abstract][Full Text] [Related]
2. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation.
Kawai Y; Taniuchi S; Okahara S; Nakamura M; Gemba M
Biol Pharm Bull; 2005 Aug; 28(8):1385-8. PubMed ID: 16079479
[TBL] [Abstract][Full Text] [Related]
3. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
4. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats.
Uehara T; Miyoshi T; Tsuchiya N; Masuno K; Okada M; Inoue S; Torii M; Yamate J; Maruyama T
Hum Exp Toxicol; 2007 Oct; 26(10):767-80. PubMed ID: 18025048
[TBL] [Abstract][Full Text] [Related]
7. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.
Hanada K; Suda M; Kanai N; Ogata H
Pharm Res; 2010 Sep; 27(9):1893-9. PubMed ID: 20552253
[TBL] [Abstract][Full Text] [Related]
11. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Ishibashi T; Yano Y; Oguma T
Br J Clin Pharmacol; 2003 Aug; 56(2):205-13. PubMed ID: 12895194
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies.
Ito K; Adachi S; Itani Y; Koyama M; Hori K; Chin R; Shintani M; Beppu K; Kawai S; Saito K
Jpn J Clin Oncol; 1999 Jun; 29(6):299-302. PubMed ID: 10418559
[TBL] [Abstract][Full Text] [Related]
14. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin.
Matsumoto Y; Ishiko O; Nakagawa E; Sumi T; Hyun Y; Ando Y; Ogita S
Oncol Rep; 2001; 8(6):1269-73. PubMed ID: 11605047
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockage of serotonin biosynthesis and circadian changes in oxaliplatin toxicity in rats.
Boughattas NA; Ben Attia M; Ixart G; Lemaigre G; Mechkouri M; Reinberg A
Chronobiol Int; 2002 Nov; 19(6):1121-36. PubMed ID: 12511030
[TBL] [Abstract][Full Text] [Related]
17. Priming reduces the bone marrow toxicity of carboplatin.
Gore ME; Hills CA; Siddik ZH; Sloane JP; Winkley AR; Smith IE; Millar JL
Eur J Cancer Clin Oncol; 1987 Jan; 23(1):75-80. PubMed ID: 3297714
[TBL] [Abstract][Full Text] [Related]
18. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
Uehara T; Tsuchiya N; Masuda A; Torii M; Nakamura M; Yamate J; Maruyama T
J Appl Toxicol; 2008 Apr; 28(3):388-98. PubMed ID: 17685399
[TBL] [Abstract][Full Text] [Related]
19. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
20. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.
Boughattas NA; Lévi F; Fournier C; Lemaigre G; Roulon A; Hecquet B; Mathé G; Reinberg A
Cancer Res; 1989 Jun; 49(12):3362-8. PubMed ID: 2720689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]